Risk Factors in SPAC Mergers

Last updated: May 20, 2026

The Risk Landscape

SPAC mergers carry a distinct risk profile that differs materially from traditional IPOs, direct listings, and private acquisitions. The blank-check structure introduces risks that do not exist in conventional public offerings — dilution from the sponsor-promote and warrants, information asymmetry between sponsors and public shareholders, and execution dependencies on redemption levels and PIPE commitments that remain uncertain until days before closing.

Between 2020 and 2023, the median de-SPAC transaction delivered negative returns to public shareholders within 12 months of closing. This aggregate underperformance was not random — it reflected systematic risks embedded in the SPAC structure that were underappreciated during the boom and, in many cases, inadequately disclosed. Understanding this risk taxonomy is essential for any participant in the SPAC market, whether as an investor, target company, sponsor, or legal advisor.

Dilution Risk

The Promote

The sponsor-promote is the original and most fundamental source of dilution in a SPAC. Sponsors typically receive 20% of the post-IPO shares for a nominal investment — often $25,000 for what becomes a $50–200 million stake. This economic transfer comes directly from public shareholders.

To illustrate: a $200 million SPAC issues 20 million public shares at $10 each. The sponsor receives 5 million founder shares for $25,000. At deal closing, the combined company has 25 million shares outstanding before considering any other issuances. The sponsor's 5 million shares represent $50 million in value that did not come from capital contributed to the trust — it came from diluting public shareholders' proportional ownership.

Some sponsors have modified the traditional 20% promote. PSTH eliminated founder shares entirely in favor of warrant-based sponsor compensation. Others have agreed to forfeit a portion of founder shares or convert them to earnout shares that vest only if the post-merger stock reaches specified price targets. These modifications reduce but do not eliminate the dilution.

Warrants

SPAC units typically include warrants — the right to purchase additional shares at $11.50 per share. When exercised, warrants increase the share count and dilute existing holders. A typical SPAC includes 1/3 to 1/2 warrant per unit, plus private placement warrants sold to the sponsor at IPO.

For a $200 million SPAC with 1/3 warrant per unit: 20 million units produce approximately 6.67 million public warrants. Add 5–10 million private placement warrants, and the total dilution from warrants alone can reach 15–20% of fully diluted shares.

Warrant dilution is contingent on exercise, which depends on the stock price exceeding $11.50 (or the cashless exercise threshold). But for any successful deal — exactly the outcome shareholders want — warrant dilution is virtually certain to materialize.

PIPE Dilution

Most de-SPAC transactions include a PIPE (Private Investment in Public Equity) to supplement the trust proceeds, particularly given that high redemptions can drain most of the trust. PIPE investors typically receive shares at $10 per share — the same price public shareholders paid at IPO — but often with better information, having conducted diligence on the specific target.

PIPE commitments can range from modest top-ups to massive financings that dwarf the original trust. When redemptions are high, PIPE investors may end up providing the majority of the combined company's cash, diluting public shareholders who remain while receiving equivalent or better terms.

Aggregate Dilution Illustration

Consider a $300 million SPAC that completes a merger valuing the target at $1.5 billion:

| Source | Shares (M) | Value at $10 | |--------|-----------|--------------| | Public shareholders (post-redemption, 60% redeemed) | 12.0 | $120M | | Sponsor promote | 7.5 | $75M | | PIPE investors | 20.0 | $200M | | Target shareholders | 120.0 | $1,200M | | Warrants (if exercised) | 15.0 | — | | Total diluted | 174.5 | — |

The original public shareholders who chose not to redeem hold 6.9% of the fully diluted company — not the 20% their $120 million trust contribution might suggest relative to the $1.5 billion valuation. This dilution arithmetic is the primary structural disadvantage of SPAC investing.

Valuation Risk

Inflated Projections

Unlike traditional IPOs, SPACs historically presented forward-looking financial projections in the S-4 registration statement, protected (until recently) by the Private Securities Litigation Reform Act's safe harbor for forward-looking statements. This created an incentive to present aggressive revenue and EBITDA forecasts to justify target valuations.

NKLA became the most prominent example. VectoIQ's merger with Nikola presented projections showing billions in revenue from hydrogen fuel-cell trucks — vehicles that were, as later revealed by a short-seller report, not yet functional. The stock peaked above $90 before collapsing below $2 as the projections proved illusory and fraud allegations emerged.

CLOV (Social Capital Hedosophia Holdings Corp III's merger with Clover Health) faced similar scrutiny. A Hindenburg Research report alleged that the company had failed to disclose a Department of Justice investigation and had presented misleading metrics in its SPAC merger filings.

Academic analysis of 2019–2021 de-SPACs found that targets missed their Year 1 revenue projections by a median of 30–40% and their Year 2 projections by 50% or more. This systematic optimism was not disclosure error — it was incentive-driven. Sponsors profit from completing deals at higher valuations; target management teams negotiate for higher prices; and the PIPE investors who validated these valuations often hedged their exposure or exited quickly after lock-up expiration.

Comparables Selection

S-4 fairness analyses frequently selected aggressive comparable companies or used forward-year multiples applied to optimistic projections. A pre-revenue electric vehicle company might be valued against Tesla's multiples rather than against traditional auto OEM metrics, producing a valuation that assumed market-leading execution before the first vehicle shipped.

QS (Kensington Capital Acquisition Corp's merger with QuantumScape) was valued at over $3 billion at merger announcement based on solid-state battery technology that was years from commercialization. The stock initially surged above $130 on retail enthusiasm before declining over 90% as commercialization timelines extended.

Execution Risk

Failed Votes and Redemption-Driven Minimum Cash Conditions

SPAC mergers require shareholder approval, and while the sponsor's founder shares (typically 20% of votes) provide a base, public shareholder opposition or apathy can threaten deals. More commonly, extreme redemption levels create execution risk through minimum cash conditions.

Most merger agreements include a minimum cash condition — the combined company must have a specified amount of cash at closing (from trust proceeds net of redemptions plus PIPE commitments) for the deal to close. When redemptions exceed expectations, this condition can fail.

In the post-boom environment (2022–2024), redemption rates regularly exceeded 90%, forcing last-minute scrambles to secure additional financing, renegotiate deal terms, or accept closing with minimal operating capital. MVST (GX Acquisition Corp II's merger with Microvast) closed with high redemptions that left the company with less cash than projected, contributing to subsequent operational and financial challenges.

Regulatory Approval Risk

Certain de-SPAC transactions require regulatory approvals beyond SEC review — antitrust clearance, CFIUS review for foreign targets, or industry-specific approvals (banking, insurance, telecommunications). These introduce timeline risk and potential deal failure.

DWAC (Digital World Acquisition Corp's merger with Trump Media & Technology Group) faced extended SEC and DOJ investigations that delayed the transaction by over two years. The regulatory complexity, combined with the political dimensions of the deal, led to multiple extensions, significant shareholder uncertainty, and eventual completion on terms that differed substantially from the original announcement.

Regulatory Risk

SEC Scrutiny and Rule Changes

The SEC's posture toward SPACs shifted dramatically between 2020 and 2024. Initial light-touch oversight during the boom gave way to targeted enforcement, staff guidance restricting projection use, and ultimately comprehensive rulemaking.

The January 2024 final rules (discussed in detail in our guide on recent SEC rule changes) fundamentally altered the SPAC regulatory landscape. Key provisions include removal of the PSLRA safe harbor for projections in de-SPAC transactions, enhanced disclosure requirements, and treatment of de-SPACs as sales of securities triggering underwriter liability.

For investors in existing SPACs, regulatory risk manifests as: (1) longer SEC review periods delaying deal timelines, (2) forced disclosure revisions that may reveal less attractive deal economics, (3) potential unwillingness of targets to pursue SPAC mergers given increased liability exposure, and (4) reduced PIPE participation from investors concerned about liability.

Accounting and Restatement Risk

SPACs have been disproportionately affected by accounting restatements. In 2021, SEC staff guidance on the classification of warrants (as equity vs. liability) forced hundreds of SPACs to restate financial statements. While largely technical, these restatements consumed management time, increased audit costs, and in some cases delayed pending mergers.

Post-merger, target companies transitioning from private to public accounting standards face elevated restatement risk. The compressed de-SPAC timeline means that financial statements included in the S-4 may not have received the same level of audit scrutiny as a traditional IPO registration statement.

Post-Merger Performance Risk

Lock-Up Expirations and Selling Pressure

PIPE investors and sponsor shares are typically subject to lock-up agreements — 6 months is standard, though terms vary. When lock-ups expire, large blocks of shares become eligible for sale, creating predictable selling pressure.

For a typical de-SPAC:

• Day 1: Public float consists only of non-redeeming SPAC shareholders
• Month 6: PIPE investor lock-up expires, potentially doubling the float
• Month 12: Sponsor/founder share lock-up expires, adding another 15–20%
• Earnout vesting: Additional shares may enter the float as price or operational milestones are achieved

Each lock-up expiration is a technical headwind. Stocks that have already declined below $10 face compounding pressure as locked-up holders sell to limit losses.

Operating Company Transition Challenges

The target company, having spent months focused on the SPAC merger rather than operations, must suddenly operate as a public company — quarterly reporting, SOX compliance, investor relations, public governance. Many de-SPAC targets are early-stage companies with limited management depth, and the transition demands can overwhelm lean teams.

Management turnover is elevated in the 12–24 months post-merger. CFO replacements are particularly common as companies discover that their private-company finance function is insufficient for public reporting requirements.

Sponsor Exit and Governance Vacuum

Sponsors who complete the de-SPAC transaction have already captured the bulk of their economic return through the promote. Their incentive to remain actively engaged with the combined company is diminished, particularly if the stock declines. Board seats held by sponsor-affiliated directors may turn over, removing whatever operational or strategic guidance the sponsor initially provided.

Information Asymmetry

Public SPAC shareholders face significant information disadvantages relative to sponsors, target management, and PIPE investors. Sponsors conduct proprietary diligence on the target. PIPE investors receive management presentations and access to data rooms that public shareholders do not see. Target management understands the business's prospects — and its problems — far better than any outside party.

The S-4 registration statement is meant to level this playing field, but the document is drafted by the parties with interests in completing the transaction. Risk factor disclosure is comprehensive in a legal sense (covering every conceivable risk) but often uninformative in a practical sense (failing to highlight which risks are most likely or most consequential for the specific transaction).

Litigation Risk

De-SPAC transactions generate litigation at elevated rates compared to traditional IPOs. Common claims include:

• Breach of fiduciary duty by the SPAC board for approving an unfavorable merger
• Securities fraud based on allegedly misleading projections or omitted information in the S-4
• Short-seller reports triggering shareholder lawsuits, as with NKLA (Hindenburg Research) and CLOV (also Hindenburg)
• Appraisal actions by shareholders contesting the per-share merger consideration

The SEC's 2024 rule changes extend potential liability to underwriters in de-SPAC transactions, increasing the litigation surface area and potentially raising the cost of capital for SPAC mergers.

Constructing a Risk Framework

For practitioners evaluating a specific SPAC merger, a systematic risk assessment should address each category with transaction-specific analysis:

Dilution: Calculate fully diluted share count under base and high-redemption scenarios, including all warrants, earnouts, and potential conversions. Express public shareholder ownership as a percentage of the fully diluted total.

Valuation: Benchmark target projections against historical performance, industry growth rates, and comparable public companies. Apply a discount to management projections based on the systematic optimism bias documented in academic literature. Stress-test the implied valuation multiples at Year 2 and Year 3 of projected financials.

Execution: Assess minimum cash condition headroom under various redemption scenarios. Evaluate the strength and composition of PIPE commitments. Identify any regulatory approvals required and their historical timeline.

Regulatory: Review SEC comment letters on the S-4 for areas of concern. Assess exposure to the 2024 rule changes, particularly regarding projection liability and underwriter exposure.

Post-merger: Model lock-up expiration dates and potential selling pressure. Evaluate management depth for public company operations. Assess the target's capital needs relative to closing cash.

The risks cataloged here are not hypothetical. Each has materialized in multiple real transactions, often in combination. The SPAC structure's unique features — the promote, the redemption right, the projection allowance, the compressed timeline — create a risk environment that requires purpose-built analytical frameworks rather than simple extension of traditional IPO or M&A risk analysis.